Out Now! Immunogenicity of poxvirus A16/G9 entry–fusion subcomplex and its restriction by A56/K2 protein informs vaccine design #MicroSky
Nature Microbiology, Published online: 10 June 2026; doi:10.1038/s41564-026-02392-6The poxvirus A16/G9 entry protein is shown to be a potent cross-protective antigen for incorporation into recombinant vaccines, but its immunogenicity in current live vaccines is restricted by the viral A56/K2 fusion suppressor complex.
